TY - JOUR
T1 - Innovative diagnostic tools for early detection of Alzheimer's disease
AU - Laske, Christoph
AU - Sohrabi, Hamid R.
AU - Frost, Shaun M.
AU - López-De-Ipiña, Karmele
AU - Garrard, Peter
AU - Buscema, Massimo
AU - Dauwels, Justin
AU - Soekadar, Surjo R.
AU - Mueller, Stephan
AU - Linnemann, Christoph
AU - Bridenbaugh, Stephanie A.
AU - Kanagasingam, Yogesan
AU - Martins, Ralph N.
AU - O'bryant, Sid E.
N1 - Funding Information:
This work was supported by the German Federal Ministry of Education and Research (BMBF, 01GQ0831 , 16SV5840 ), the Deutsche Forschungsgemeinschaft ( DFG SO932-2 ) and the European Union ( FP7-ICT-2011-288551 ). RNM is the founder and owns stock in Alzhyme. HRS is working as a Site Lead neuropsychologist or Neuropsychological rater for Takeda, Wyeth, and Pfizer. None of the authors of this manuscript have any biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2015 The Alzheimer's Association.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Current state-of-the-art diagnostic measures of Alzheimer's disease (AD) are invasive (cerebrospinal fluid analysis), expensive (neuroimaging) and time-consuming (neuropsychological assessment) and thus have limited accessibility as frontline screening and diagnostic tools for AD. Thus, there is an increasing need for additional noninvasive and/or cost-effective tools, allowing identification of subjects in the preclinical or early clinical stages of AD who could be suitable for further cognitive evaluation and dementia diagnostics. Implementation of such tests may facilitate early and potentially more effective therapeutic and preventative strategies for AD. Before applying them in clinical practice, these tools should be examined in ongoing large clinical trials. This review will summarize and highlight the most promising screening tools including neuropsychometric, clinical, blood, and neurophysiological tests.
AB - Current state-of-the-art diagnostic measures of Alzheimer's disease (AD) are invasive (cerebrospinal fluid analysis), expensive (neuroimaging) and time-consuming (neuropsychological assessment) and thus have limited accessibility as frontline screening and diagnostic tools for AD. Thus, there is an increasing need for additional noninvasive and/or cost-effective tools, allowing identification of subjects in the preclinical or early clinical stages of AD who could be suitable for further cognitive evaluation and dementia diagnostics. Implementation of such tests may facilitate early and potentially more effective therapeutic and preventative strategies for AD. Before applying them in clinical practice, these tools should be examined in ongoing large clinical trials. This review will summarize and highlight the most promising screening tools including neuropsychometric, clinical, blood, and neurophysiological tests.
KW - Alzheimer's disease
KW - Diagnostic tools
KW - Early detection
KW - Noninvasive tests
KW - Screening tests
UR - http://www.scopus.com/inward/record.url?scp=84929264128&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2014.06.004
DO - 10.1016/j.jalz.2014.06.004
M3 - Review article
C2 - 25443858
AN - SCOPUS:84929264128
SN - 1552-5260
VL - 11
SP - 561
EP - 578
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 5
ER -